Skip to content

Study · Randomized controlled trial · 2016

5 results

Interactions Between Neurokinin B and Kisspeptin in Mediating Estrogen Feedback in Healthy Women.

Skorupskaite K, George JT, Veldhuis JD, Millar RP, Anderson RA

The Journal of clinical endocrinology and metabolism16 Sept 2016Cited by 33 (Europe PMC)

PMID27636018 (opens in a new tab)PMCIDPMC5155690 (opens in a new tab)DOI10.1210/jc.2016-2132 (opens in a new tab)PepBankPUB-27636018
Download PDFPubMedAsk about this study
Jump to 5 results

Summary

ContextKisspeptin and neurokinin B (NKB) are obligate for normal gonadotropin secretion, but their hierarchy is unexplored in normal women.ObjectiveTo investigate the interaction between kisspeptin and NKB on estrogen-regulated LH secretion.DesignWomen were treated with neurokinin-3 receptor (NK3R) antagonist followed by transdermal estradiol to induce LH secretion 48 hours later, with kisspeptin-10 or vehicle infusion during estrogen administration in a 2-way crossover study.SettingClinical research facility.Patients or other participantsHealthy females with regular menses.Intervention(s)NK3R antagonist AZD4901 40 mg twice daily orally was taken from cycle day 4-6 for 6 days (n = 10, with 10 no treatment controls). Transdermal estradiol patches (200 μg/d) were applied after 5 days of NK3R antagonist treatment. At 24-hour estradiol treatment, women were randomized to 7-hour kisspeptin-10 (4 μg/kg/h) or vehicle iv infusion, with the alternate infusion in a subsequent cycle.Main outcome measure(s)Plasma gonadotropin and estradiol secretion.ResultsAfter an initial suppression, LH secretion was increased 48 hours after estradiol treatment. Kisspeptin-10 increased LH secretion during the inhibitory phase, and LH remained elevated beyond the discontinuation of kisspeptin-10 infusion. NK3R antagonist decreased LH pulse frequency (0.5 ± 0.2 vs 0.7 ± 0.2 pulses/h, P < .05) and stimulated FSH response to kisspeptin-10 infusion (10.7 ± 11.0 vs 5.0 ± 3.6 IU/L, P < .05) with a nonsignificant rise in LH. The duration of LH response was blunted, with LH being lower at 48 hours (7.5 ± 4.8 vs 15.0 ± 11.4 IU/L, P < .05).ConclusionsThese data demonstrate that NKB signaling regulates GnRH/LH secretion in normal women, and is predominantly proximal to kisspeptin in mediating estrogenic positive and negative feedback on LH secretion.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study5

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In healthy women during estradiol treatment, kisspeptin‑10 infusion increased LH secretion during the inhibitory phase compared with vehicle.

    In plain wordsIn healthy women, kisspeptin‑10 infusion raised LH release compared with a vehicle infusion.

    Peptide
    Kisspeptin-10
    Outcome
    IncreaseLH secretion during kisspeptin-10 infusion
    Study

    n: not reported in source

    Comparator
    Vehicle infusion
    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    4 μg/kg/h · intravenous infusion · 7 hoursAs given in this study (human).

    Source sentences

    Summary
    Kisspeptin-10 increased LH secretion during the inhibitory phase
    2 context sentences
    Summary · context
    Women were treated with neurokinin-3 receptor (NK3R) antagonist followed by transdermal estradiol to induce LH secretion 48 hours later, with kisspeptin-10 or vehicle infusion during estrogen administration in a 2-way crossover study.
    Summary · context
    At 24-hour estradiol treatment, women were randomized to 7-hour kisspeptin-10 (4 μg/kg/h) or vehicle iv infusion, with the alternate infusion in a subsequent cycle.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In healthy women, LH remained elevated after the kisspeptin‑10 infusion was discontinued.

    In plain wordsIn healthy women, LH stayed raised after the kisspeptin‑10 infusion stopped.

    Peptide
    Kisspeptin-10
    Outcome
    IncreaseLH secretion after kisspeptin-10 infusion ended
    Study

    n: not reported in source

    Comparator
    Vehicle infusion
    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    4 μg/kg/h · intravenous infusion · 7 hoursAs given in this study (human).

    Source sentences

    Summary
    and LH remained elevated beyond the discontinuation of kisspeptin-10 infusion.
    2 context sentences
    Summary · context
    Women were treated with neurokinin-3 receptor (NK3R) antagonist followed by transdermal estradiol to induce LH secretion 48 hours later, with kisspeptin-10 or vehicle infusion during estrogen administration in a 2-way crossover study.
    Summary · context
    At 24-hour estradiol treatment, women were randomized to 7-hour kisspeptin-10 (4 μg/kg/h) or vehicle iv infusion, with the alternate infusion in a subsequent cycle.

Studies that did not test the peptide alone3

In this study, Kisspeptin-10 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Kisspeptin-10.

  1. 03HumanNot a test of Kisspeptin-10 aloneRandomized controlled trialEfficacy outcome

    In healthy women, treatment with the NK3R antagonist AZD4901 stimulated the FSH response to kisspeptin‑10 infusion.

    In plain wordsIn healthy women, the NK3R blocker raised the FSH response to kisspeptin‑10 compared with no blocker.

    Peptide
    Kisspeptin-10
    Outcome
    IncreaseFSH response to kisspeptin-10 with NK3R antagonist
    Study

    n: not reported in source

    Comparator
    Women without NK3R antagonist
    Outcome group
    Sex hormones and fertility · Endocrine and hormones

    Measurements

    FSH response
    10.7 IU/L
    NK3R antagonist
    FSH response
    5 IU/L
    without antagonist

    Source sentences

    Summary
    stimulated FSH response to kisspeptin-10 infusion (10.7 ± 11.0 vs 5.0 ± 3.6 IU/L, P < .05)
    2 context sentences
    Summary · context
    Women were treated with neurokinin-3 receptor (NK3R) antagonist followed by transdermal estradiol to induce LH secretion 48 hours later, with kisspeptin-10 or vehicle infusion during estrogen administration in a 2-way crossover study.
    Summary · context
    At 24-hour estradiol treatment, women were randomized to 7-hour kisspeptin-10 (4 μg/kg/h) or vehicle iv infusion, with the alternate infusion in a subsequent cycle.

    In this study, Kisspeptin-10 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Kisspeptin-10.

  2. 04HumanNot a test of Kisspeptin-10 aloneRandomized controlled trialEfficacy outcome

    In healthy women, the NK3R antagonist was followed by a nonsignificant rise in LH response to kisspeptin‑10.

    In plain wordsIn healthy women, the NK3R blocker did not significantly change the LH response to kisspeptin‑10.

    Peptide
    Kisspeptin-10
    Outcome
    No significant changeLH response to kisspeptin-10 with NK3R antagonist
    Study

    n: not reported in source

    Comparator
    Women without NK3R antagonist
    Outcome group
    Sex hormones and fertility · Endocrine and hormones

    Source sentences

    Summary
    with a nonsignificant rise in LH.
    2 context sentences
    Summary · context
    Women were treated with neurokinin-3 receptor (NK3R) antagonist followed by transdermal estradiol to induce LH secretion 48 hours later, with kisspeptin-10 or vehicle infusion during estrogen administration in a 2-way crossover study.
    Summary · context
    At 24-hour estradiol treatment, women were randomized to 7-hour kisspeptin-10 (4 μg/kg/h) or vehicle iv infusion, with the alternate infusion in a subsequent cycle.

    In this study, Kisspeptin-10 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Kisspeptin-10.

  3. 05HumanNot a test of Kisspeptin-10 aloneRandomized controlled trialEfficacy outcome

    In healthy women given kisspeptin‑10, the NK3R antagonist blunted the duration of the LH response, with lower LH at 48 hours.

    In plain wordsIn healthy women, the NK3R blocker shortened the LH response to kisspeptin‑10, with lower LH at 48 hours.

    Peptide
    Kisspeptin-10
    Outcome
    DecreaseLH at 48 hours after NK3R antagonist
    Study

    n: not reported in source

    Comparator
    Women without NK3R antagonist
    Outcome group
    Sex hormones and fertility · Endocrine and hormones

    Measurements

    LH at 48 hours
    7.5 IU/L
    NK3R antagonist
    LH at 48 hours
    15 IU/L
    without antagonist

    Source sentences

    Summary
    The duration of LH response was blunted, with LH being lower at 48 hours (7.5 ± 4.8 vs 15.0 ± 11.4 IU/L, P < .05).
    2 context sentences
    Summary · context
    Women were treated with neurokinin-3 receptor (NK3R) antagonist followed by transdermal estradiol to induce LH secretion 48 hours later, with kisspeptin-10 or vehicle infusion during estrogen administration in a 2-way crossover study.
    Summary · context
    At 24-hour estradiol treatment, women were randomized to 7-hour kisspeptin-10 (4 μg/kg/h) or vehicle iv infusion, with the alternate infusion in a subsequent cycle.

    In this study, Kisspeptin-10 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Kisspeptin-10.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    9 Oct 2026, 18:17 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.